a public good project by the
Synthesis
Company
of California

© 2026

Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer | doi.page

0 citations0 references

Google Scholar doi.org

Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer

BioDrugs·2012·Vol. 26(6), pp. 431–435

Citations Over Time

Gillian M. Keating, Katherine A. Lyseng‐Williamson, James E. Frampton

Related Papers

→ Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid Cancer(2022)30 cited
→ Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect(2023)28 cited
→ Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report(2018)10 cited
→ Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer(2012)1 cited
Experience with vandeta nib in medullary thyroid cancer(2014)